Bovhyaluronidase azoximer

A clinical case of consistent use of botulinum toxin type A (BTA) and azoximer bovhialuronidase (BA) in a 69-year-old patient who suffered an ischemic stroke (II) with right-sided hemiparesis is presented. BTA (incobotulotoxin) was injected under ultrasound control (ultrasound) into the muscles of the target pathological patterns at a dose of 500 units. After 3 weeks, under the control of ultrasound navigation, BA was injected into the 2 most fibrotic shoulder muscles at a dose of 3.000 IU (1.500 IU each). The effectiveness of therapy was monitored using a modified Ashworth scale (MAS), goniometry, and electromyography. A decrease in the severity of the leading pattern of spasticity of the muscles of the upper extremity (on the MAS scale) after injection of BTA was found. After consistent application of BA, a distinct change in the structure of muscle tissue and a decrease in tone in spastic muscles were recorded. The results obtained confirm the safety of botulinum therapy and the good tolerability and efficacy of Xeomin in a patient with spasticity with contracture formation after AI. The introduction of ASTHMA after botulinum therapy makes it possible to increase the elasticity of spastic muscles by reducing the severity of fibrous changes and improving motor function.

Lower urinary tract symptoms (LUTS) occur in 90% of middle-aged, elderly and senile men and are usually associated with benign prostatic hyperplasia (BPH). The prevalence of BPH and its negative impact on all aspects of a man's life force modern scientists to search for optimal and safe treatment strategies.

To evaluate the efficiency and safety of bovhyaluronidase azoximer (Longidaza, lyophilisate for injection and rectal suppositories 3,000 IU) in combination with the alpha-blocker tamsulosin in the treatment of patients with LUTS associated with BPH.

A total of 229 patients with LUTS associated with BPH were included in the study. They were randomly divided into an experimental group (n=118) and a control group (n=111). Patients in the experimental group received the drug Longidaza in 2 dosage forms together with tamsulosin, while in the control group, tamsulosin was administered as monotherapy. The evaluation was carried out in outpatient settings and included five timepoints. The duration of follow-up of patients throughout the study was no more than 138 days.

There were no differences between patients in the experimental and control groups in terms of baseline characteristics and duration of LUTS due to BPH (1.51+/-1.04 vs. 1.46+/-0.85 years, respectively). In the experimental group, there was a significantly more pronounced decrease in the level of symptoms according to the International Prostate Symptom Score (IPSS) at 60 (+/-1) and 130 (+/-3) days from the start of therapy compared to the baseline level (p = 0.031 and 0.004, respectively). Throughout the study, total prostate volume moderately decreased in all patients. According to the analysis of covariance, a significantly more pronounced decrease in the total NIH-CPSI score was also observed in the experimental group. In addition, in the main group the quality of life increased by 85.71%, while in the control group the positive dynamics was in 71.43% of cases. During laboratory examination it was found that the total PSA level remained virtually unchanged in patients of both groups, There were 5 adverse events (AE) in the experimental group and 14 in the control group, and none of the AE prevented the patients from continuing to participate in the study.

Our results indicate greater efficiency and safety of combination therapy with Longidaza and tamsulosin in patients with LUTS due to BPH compared to monotherapy with tamsulosin.